Research programme: antibody therapeutics - Ix Therapeutics
Latest Information Update: 29 Jul 2021
Price :
$50 *
At a glance
- Originator Ix Therapeutics
- Class Antibodies; Antineoplastics; Immunotherapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Colorectal cancer; Lung cancer
Most Recent Events
- 22 Jul 2021 Research programme: antibody therapeutics - Ix Therapeutics/Veraxa Biotech is available for licensing as of 31 Mar 2021
- 22 Jul 2021 Ix Therapeutis plans a clinical trial in cancer (Indivumed website, July 2021)
- 18 Mar 2021 Ix Therapeutics enters in an agreement with VERAXA Biotech for Droplet Microfluidic technology